Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Penpulimab in Neoadjuvant HER2-low Breast Cancer
NCT05726175Phase 2Unknown
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2023
- Primary completion
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin, penpulimab in breast cancer, sponsored by West China Hospital of Sichuan University. Status: unknown.
02
Drugs
disitamab vedotinpenpulimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05726175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05726175.